JSPR Projected Dividend Yield
Jasper Therapeutics Inc ( NASDAQ : JSPR )Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. Co. is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. Co.'s lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. 21 YEAR PERFORMANCE RESULTS |
JSPR Dividend History Detail JSPR Dividend News JSPR Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |